A Clinical trail on accurate administration of tacrolimus based on population pharmacokinetic model in patients with lung transplantation

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036727

Enrollment

Unknown

Registered

2020-08-24

Start date

2020-09-30

Completion date

Unknown

Last updated

2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Transplantation

Interventions

Test group:the dosage was adjusted according to the nonlinear model

control group: the dosage was adjusted according to the linear model

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with Lung transplantation ,male and female; 2) No age restriction; 3) Without any other organ transplant , the donor source is the DCD donor; 4) No resistance and tolerance during the use of tacrolimus, 5) Good compliance 6) Fully understand the purpose of this study and the possible adverse reactions, voluntarily participate in and sign the signatory.

Exclusion criteria

Exclusion criteria: 1)The occurrence of intolerable adverse reactions; 2) Combined organ transplantation; 3) Can not be given tacrolimus orally; 4) Any form of substance abuse or mental illness; 5) Those who did not follow the study plan during the study (poor compliance).

Design outcomes

Primary

Measure	Time frame
blood concentration of FK506 ;	—

Countries

China

Contacts

Public ContactPan Yan

Shanghai Chest Hospital

tt37py@qq.com+86 13917527725

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026